<DOC>
	<DOCNO>NCT01505127</DOCNO>
	<brief_summary>The purpose study confirm efficacy triple therapy TAK-438 , Amoxicillin Clarithromycin , twice daily ( BID ) demonstrate non-inferiority triple therapy Lansoprazole , Amoxicillin Clarithromycin H. pylori-positive patient scar gastric duodenal ulcer .</brief_summary>
	<brief_title>Efficacy TAK-438 , Amoxicillin Clarithromycin First Line Eradication H. Pylori</brief_title>
	<detailed_description />
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>1 . Participants must H. pyloripositive patient baseline ( Visit 1 ) 2 . Participants must endoscopically confirm scarred gastric ulcer duodenal ulcer baseline ( Visit 1 ) . However , history ulcer confirm medical interview previous medical record , Participants whose gastric ulcer scar duodenal ulcer scar disappear may include study . 3 . Outpatient ( include inpatient examination ) 1 . Participants receive H.pylori eradication treatment 2 . Participants either acute upper gastrointestinal bleeding , gastric ulcer [ mucosal defect ( white coat include clot adherence ) 3 mm large size ] , duodenal ulcer [ mucosal defect ( white coat include clot adherence ) 3 mm large size ] , acute gastric mucosal lesion ( AGML ) , acute duodenal mucosal lesion ( ADML ) endoscopic examination baseline ( Visit 1 ) . However , participant gastric erosion duodenal erosion may include study . 3 . Participants receive scheduled undergo surgery affect gastric acid secretion ( ex , resection upper gastrointestinal tract , vagotomy , etc ) 4 . Participants treat medicinal treatment ( ex , perforation , pyloric stenosis large hemorrhage , etc ) 5 . Participants previous current history ZollingerEllison syndrome , gastric acid hypersecretion disorder 6 . Participants hepatic renal impairment receive treatment colchicine 7 . Participants history hypersensitivity allergy TAK438 ( include excipients ) , PPIs , penicillin antibiotic , macrolide antibiotic , antitrichomonal agent 8 . Participants infectious mononucleosis 9 . Participants organic disease brain spinal cord</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>